Krempa David 4

What Happened David Krempa, Chief Business Officer of Eton Pharmaceuticals (ETON), reported exercising/converting a derivative (code M) that resulted in the acquisition of 10,000 shares on July 12, 2026. The filing also shows a simultaneous disposition of 10,000 shares at $0.00 (reported as $0 proceeds), consistent with a net settlement or shares withheld in connection with the exercise.

Key Details

• Transaction date: July 12, 2026; Form 4 filed July 13, 2026 (timely).
• Acquired: 10,000 shares via exercise/conversion of a derivative (code M). Price listed as N/A for the acquired shares.
• Disposed: 10,000 shares at $0.00 for $0 (reported as derivative disposition).
• Shares owned after the transaction: not specified in the provided filing summary.
• Footnote: A prior grant (July 12, 2022) of 40,000 restricted stock units vests in four equal annual installments beginning July 12, 2023.
• Remark: The reporting person authorized another individual to file this Form 4 on their behalf.

Context Derivative exercises often result in simultaneous withholding or transfer of some shares to cover exercise costs or tax withholding; the $0.00 disposition here is consistent with a net settlement/withholding rather than an open-market sale. This filing is procedural in nature—no cash proceeds are reported—and was filed promptly.